Fast-track NASH Drug Discovery with Organ-on-Chip Studies
Discover how Organ-on-Chip studies can help you screen new NASH therapeutic candidates, investigate mechanisms of action and generate actionable data in weeks.
Human-relevant Organ-on-Chip data can be used to plan and optimize your clinical trial design, prioritize pre-clinical candidates and integrate effects on different target cell types of the liver.
Studies as a Service
Organ-on-Chip assays can provide quicker and more human relevant data about your therapeutic candidates than standard rodent and liver tissue studies.
Our team will work with you to design your study, acquire compounds, source cells and meet your research goals.
All studies are performed and analysed using our PhysioMimix™ OOC platform. We work with you to tailor reporting at the completion of study.
NASH Drug Discovery Using Human Organ-On-Chips
CN Bio’s NAFLD/NASH assays enable long term in vitro liver cultures and modelling of different stages of NAFLD/NASH disease in a range of culture conditions.
They are ideally suited to understanding the efficacy of novel anti-NASH therapeutics and can provide data on a range of different target pathways.
A “Must Have” for Hepatic Cultures
“The CN Bio MPS system allows hepatic cultures to be grown for weeks with low signs of cytotoxicity or hepatocytes de-differentiation detectable; CN Bio has developed an efficient proprietary protocol to model NASH that show really high homology with murine models of NASH in terms of transcriptome, inflammatory profiling and pathophysiological events crucial for disease progression”
“The hepatic co-cultures of hepatocytes, Kupffer and stellate cells that I have tested also behave as expected in vivo with regards to intracellular signalling pathways (such as TGFβ signalling) thus allowing to model chronic liver disease pathophysiology”
“I think that the PhysioMimix OOC system will become a “must have” piece of equipment for labs focussing on liver pathophysiology and tissue-to-tissue interactions.”
Michele Vacca, MD PhD
Clinician Research Associate at the Institute of Metabolic Science, University of Cambridge
(CN Bio collaborator)
NASH therapies, in demand
Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed countries. NAFLD is a spectrum of pathologies ranging from benign hepatic steatosis through to non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and liver cancer.
Despite this, drug discovery for liver therapeutics needs to improve:
- Clinical trials are resource intensive, requiring large cohorts and years to fully assess a drug’s efficacy and toxicity in patients
- Animal models displaying the full spectrum of NAFLD/NASH pathophysiology are lacking
- There is a lack of translatability from animal models to humans
Mimicking human NAFLD/NASH physiology
CN Bio NAFLD/NASH is one of the most advanced in vitro models currently available. Studies have shown that the model is able to provide detailed data quickly on keys aspects of the human disease:
- Intracellular fat accumulation/ Hepatic steatosis
- Inflammation
- Fibrosis
Human-relevant preclinical model for Drug Development
The CN Bio NAFLD/NASH model is:
- A quick and reliable way (average 8 weeks) to screen and investigate mechanisms of action for compounds.
- Model this complex human metabolic disease in an advanced and physiologically-relevant model at a reduced cost.
- Provide efficacy data translatable to clinical studies quickly.
If you are studying NASH/NAFLD and would like to discuss Organ-on-Chip studies, please contact us using the form below or email; enquiries@cn-bio.com
Size 140KB
Human organ
mimics
Powerful new
data
Translatable
results
COMPANY HEAD OFFICE INFORMATION:
332 Cambridge Science Park
Milton Road
Cambridge
CB4 0WN
+44 (0) 1223 737941
enquiries@cn-bio.com
FOR PRODUCT, SERVICES AND MARKETING ENQUIRIES:
+44 (0) 1223 737941
enquiries@cn-bio.com
CN BIO INNOVATIONS LIMITED REGISTERED OFFICE:
30 Upper High Street, Thame,
Oxfordshire, OX9 3EZ.
Registered No. 06517359.
VAT No. 978184563